logging in or signing up ANAPHYLAXIS Moiloa Download Post to : URL : Related Presentations : Let's Connect Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Copy embed code: Embed: Flash iPad Dynamic Copy Does not support media & animations Automatically changes to Flash or non-Flash embed WordPress Embed Customize Embed URL: Copy Thumbnail: Copy The presentation is successfully added In Your Favorites. Views: 3040 Category: Entertainment License: All Rights Reserved Like it (0) Dislike it (0) Added: March 19, 2011 This Presentation is Public Favorites: 1 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript ANAPHYLAXIS: ANAPHYLAXIS Dr Dineo Moiloa EM RegistrarLEARNING OBJECTIVES: Knowledge of the different mechanisms which cause anaphylaxis and the agents which are most likely to cause it; Be able to recognize the signs and symptoms of anaphylaxis; Understand how to treat anaphylaxis LEARNING OBJECTIVESLECTURE OBJECTIVES: Definition Introduction Epidemiology Pathophysiology Aetiology Clinical presentation Management Prevention LECTURE OBJECTIVESCase study: You respond to an P1 call at an upmarket restaurant. Metro Control says there is a ‘collapsed’ patient. On arrival, a 25-year old tourist is unresponsive with an audible stridor . Her skin is red and blotchy, and feels cold and clammy. Her friend mumbles something about a ‘pen’ she uses when she gets very sick. What do you do? Case studyDEFINITION: Ana (without); phylaxis (protection/guard) An acute multi-system severe Type I hypersensitivity reaction. Anaphylaxis is a life threatening condition. True vs pseudo-anaphylaxis. DEFINITIONGell & Coombs: Type I : Mediated by IgE Type II : Mediated by anti-tissue Ab IgG and IgM Type III : Mediated by immune complexes Type IV : Cell-mediated immune complexes Gell & CoombsINTRODUCTION: INTRODUCTIONINTRODUCTION: Anaphylaxis – a syndrome with varied mechanisms, clinical presentations, and severity. An acute life-threatening reaction. Usually mediated by an immunologic mechanism, allergic anaphylaxis, but not always. Includes non-allergic anaphylaxis (formerly referred to as an anaphylactoid reaction). Results from the release of mast- basophil mediators. INTRODUCTIONANAPHYLACTIC SHOCK: Anaphylaxis asociated with systemic vasodilation ( Hypotension, fainting, collapse, LOC) and/or severe bronchoconstriction ( stridor , respiratory compromise). ANAPHYLACTIC SHOCKPseudoanaphylaxis: Anaphylactoid reactions are caused by activation of mast cells and release of the same mediators, but without the involvement of IgE antibodies . Management is similar to anaphylaxis. PseudoanaphylaxisEPIDEMIOLOGY: 50/100 000 p/yr Young people and females high risk 1-15% at risk every year 1500 deaths p/yr Global increasing rates EPIDEMIOLOGYPATHOPHYSIOLOGY: PATHOPHYSIOLOGYPATHOPHYSIOLOGY: An allergic reaction results from the interaction of an allergen with specific IgE antibodies. IgE antibodies are bound to Fc receptors for IgE on mast cells and basophils . This leads to activation and degranulation of the mast cell PATHOPHYSIOLOGYPATHOPHYSIOLOGY: Release of preformed mediators stored in granules, e.g. Histamine, tryptase , heparin, cytokines, chymase,etc Other newly-formed mediators synthesised rapidly, e.g. prostaglandin D2, leukotriene B4, PAF, LTC4, LTD4, and LTE4. Eosinophils may play pro-inflammatory role (release of cytotoxic granule-associated proteins) or anti-inflammatory role (e.g., metabolism of vasoactive mediators). PATHOPHYSIOLOGYPATHOPHYSIOLOGY: These mediators are responsible for the clinical features in anaphylaxis. Rapid systemic release of large quantities of mediators will cause capillary leakage and mucosal oedema, resulting in shock and/or asphyxia. PATHOPHYSIOLOGYPATHOPHYSIOLOGY: PATHOPHYSIOLOGYAETIOLOGY: AETIOLOGYAETIOLOGY: Common causes of anaphylaxis ( IgE -mediated) Foods Bee and wasp stings Drugs Latex rubber AETIOLOGYAETIOLOGY: AETIOLOGY Foods that cause anaphylaxis Peanuts Fish Shelfish Eggs Milk SesameCauses of anaphylaxis: Causes of anaphylaxis Direct activation of mast cells - opiates, tubocurare , dextran,radiocontrast dyes Mediators of arachidonic acid metabolism - Aspirin (ASA) - Nonsteroidal anti-inflammatory drugs (NSAIDs) Mechanism unknown - SulphitesOther Causes of anaphylaxis: Other Causes of anaphylaxis Exercise-induced cold-induced idiopathicCLINICAL EFFECTS: CLINICAL EFFECTSFrequency of symptoms in Anaphylaxis: Frequency of symptoms in AnaphylaxisEffects of mast cell mediators: PHYSIOLOGICAL EFFECT CLINICAL EFFECT DANGER Capillary leakage Urticaria Angioedema Laryngeal oedema Hypotension Asphyxia Hypotension Mucosal oedema Laryngeal oedema Rhinitis Asthma Respiratory arrest Smooth muscle contraction Asthma Abdominal pain Respiratory arrest Effects of mast cell mediatorsCLINICAL EFFECTS: Systemic effects of histamine release. Minutes to hours Type of allergen Mode of transmission Symptoms may recur within 72hrs with no further exposure to allergen : 1-20% (Biphasic anaphylaxis) CLINICAL EFFECTSCLINICAL EFFECTS: SKIN : Hives, Itchiness, flushing, swelling of lips, tongue or throat. RESP : SOB, wheeze, stridor , Hypoxia GIT : Abdo cramps, diarrhoea, vomiting CVS : Coronary artery spasm, MI, Dysrhytmia CNS : Light-headedness, LOC (Low BP) Loss of bladder control & muscle tone Anxiety CLINICAL EFFECTSMANAGEMENT: Case-specific Follow ACLS protocol Remove allergen DRUGS : Adrenaline Glucagon Anti-histamine Inotropes Corticosteroids Isoprotenerol B2 agonist (inhaled) IV fluids Racemic Adrenaline Oxygen MANAGEMENTMANAGEMENT: ABCDEFG Adrenaline Adrenaline Adrenaline Adrenaline alleviates bronchoconstriction through B2 adrenoR stimulation; helps prevent cardiovascular collapse through cardiac B1 R stimulation MANAGEMENTPREVENTION: Allergy tests Allergy ‘action plan’ : Education Medic-alert Epi -pen Avoid triggers Immunotherapy/ Desensitization PREVENTIONQUESTIONS: ? ? ? ? ? QUESTIONSTAKE HOME POINTS: Anaphylaxis is a life-threatening condition. Recognise Sx early ACLS guidelines Adrenaline for severe cases TAKE HOME POINTSThank you: Thank you You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.